Budesonide pMDI
Sponsors
AstraZeneca
Conditions
AsthmaChronic Obstructive Pulmonary Disease
Phase 3
A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD Patients
CompletedNCT00206154
Start: 2005-04-30End: 2006-12-31Target: 1500Updated: 2009-03-27
A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents
CompletedNCT01444430
Start: 2011-12-31End: 2015-10-31Updated: 2016-12-15
A 12-Week Study in Asthmatic Children Ages 6 to <12 Years, Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared With Budesonide pMDI 80 μg
CompletedNCT02091986
Start: 2014-04-30End: 2016-04-30Updated: 2017-04-10